Skip to main content
Erschienen in: Clinical and Experimental Medicine 3/2011

01.09.2011 | Original Article

B7-H4 expression in various tumors determined using a novel developed monoclonal antibody

verfasst von: Yun Qian, Ling Shen, Linfang Cheng, Zhigang Wu, Hangping Yao

Erschienen in: Clinical and Experimental Medicine | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

B7-H4, a new member of the B7 family, may participate in the negative regulation of cell-mediated immunity, while aberrant B7-H4 expression is detected in some tumors and it participates in the occurrence and development of the tumors. In this study, we developed one monoclonal antibody (mAb) whose clone No. was 4H8 against the extracellular domains of B7-H4 through immunization of Balb/c mice with the 3T3-mB7-H4 cells that expressed extrinsic B7-H4 stably. And we detected the expression characteristics of B7-H4 in various tumors using 4H8 mAb by enzyme-linked immunosorbent assay (ELISA), immunoprecipitation and immunohistochemistry (IHC) analysis. B7-H4 expression was significantly higher in the tumor tissues derived from uterus, breast, and colon than in their corresponding normal tissues. Further, the B7-H4 expression was related to the stage of the tumors. In contrast, B7-H4 expression did not differ significantly between the tumor tissues derived from the stomach and liver and the normal tissues. Different expression levels of B7-H4 in the tumors indicated that B7-H4 may be involved in tumor formation and development. Specific mAbs against B7-H4 will be useful in studying the role of B7-H4 in tumor pathogenesis and pathological process.
Literatur
1.
Zurück zum Zitat Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, Chapoval AI, Flies DB, Bajorath J, Chen L (2003) B7–H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18:849–861PubMedCrossRef Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, Chapoval AI, Flies DB, Bajorath J, Chen L (2003) B7–H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18:849–861PubMedCrossRef
2.
Zurück zum Zitat Chen L (2004) Co-inhibitory molecules of the B7- CD28 family in the control of T cell immunity. Nat Rev Immunol 4:336–347PubMedCrossRef Chen L (2004) Co-inhibitory molecules of the B7- CD28 family in the control of T cell immunity. Nat Rev Immunol 4:336–347PubMedCrossRef
3.
Zurück zum Zitat Schwartz RH (1990) A cell culture mode for T lymphocyte clonal anergy. Science 248:l349–1356CrossRef Schwartz RH (1990) A cell culture mode for T lymphocyte clonal anergy. Science 248:l349–1356CrossRef
4.
Zurück zum Zitat Chambers CA (2001) The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 22:217–223PubMedCrossRef Chambers CA (2001) The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 22:217–223PubMedCrossRef
5.
Zurück zum Zitat Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, Zhu Y, Flies DB, Tamada K, Chen L (2003) Genomic organization and expression analysis of B7–H4, an immune inhibitory molecule of the B7 family. J Immunol 171:4650–4654PubMed Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, Zhu Y, Flies DB, Tamada K, Chen L (2003) Genomic organization and expression analysis of B7–H4, an immune inhibitory molecule of the B7 family. J Immunol 171:4650–4654PubMed
6.
Zurück zum Zitat Yigit R, Massuger LF, Figdor CG, Torensma R (2010) Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 117:366–372PubMedCrossRef Yigit R, Massuger LF, Figdor CG, Torensma R (2010) Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 117:366–372PubMedCrossRef
7.
Zurück zum Zitat Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, Wang X (2006) B7–H3 and B7–H4 expression in non-small-cell lung cancer. Lung Cancer 53:143–151PubMedCrossRef Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, Wang X (2006) B7–H3 and B7–H4 expression in non-small-cell lung cancer. Lung Cancer 53:143–151PubMedCrossRef
8.
Zurück zum Zitat Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, Liu W, Pilkington G, Papkoff J (2005) The immunomodulatory protein B7–H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 306:128–141PubMedCrossRef Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, Liu W, Pilkington G, Papkoff J (2005) The immunomodulatory protein B7–H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 306:128–141PubMedCrossRef
9.
Zurück zum Zitat Cheng L, Jiang J, Gao R, Wei S, Nan F, Li S, Kong B (2009) B7–H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer 19:1481–1486PubMedCrossRef Cheng L, Jiang J, Gao R, Wei S, Nan F, Li S, Kong B (2009) B7–H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer 19:1481–1486PubMedCrossRef
10.
Zurück zum Zitat Jiang J, Zhu Y, Wu C, Shen Y, Wei W, Chen L, Zheng X, Sun J, Lu B, Zhang X (2010) Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother [Epub ahead of print] Jiang J, Zhu Y, Wu C, Shen Y, Wei W, Chen L, Zheng X, Sun J, Lu B, Zhang X (2010) Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother [Epub ahead of print]
11.
Zurück zum Zitat Qian Y, Yao HP, Cheng LF, Shen L, Gu LJ, Tao L, Zhang LH (2009) Expression and identification of recombinant mouse gene B7–H4. J Zhejiang Univ Med Sci 38:117–124 Qian Y, Yao HP, Cheng LF, Shen L, Gu LJ, Tao L, Zhang LH (2009) Expression and identification of recombinant mouse gene B7–H4. J Zhejiang Univ Med Sci 38:117–124
12.
Zurück zum Zitat Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, Wang MH (2006) Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther 5:1179–1186PubMedCrossRef Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, Wang MH (2006) Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther 5:1179–1186PubMedCrossRef
13.
Zurück zum Zitat Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG (2000) Monoclonal antibodies. Mol Pathol 53:111–117PubMedCrossRef Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG (2000) Monoclonal antibodies. Mol Pathol 53:111–117PubMedCrossRef
14.
Zurück zum Zitat Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed
15.
Zurück zum Zitat Zang XX, Loke P, Kim J, Murphy K, Waitz R, Allison JP (2003) B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 100:10388–10392PubMedCrossRef Zang XX, Loke P, Kim J, Murphy K, Waitz R, Allison JP (2003) B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 100:10388–10392PubMedCrossRef
16.
Zurück zum Zitat Prasad DVR, Richards S, Mai XM, Dong C (2003) B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18:863–873PubMedCrossRef Prasad DVR, Richards S, Mai XM, Dong C (2003) B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18:863–873PubMedCrossRef
17.
Zurück zum Zitat Cheng L, Jiang J, Gao R, Wei S, Nan F, Li S, Kong B (2009) B7–H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer 19:1481–1486PubMedCrossRef Cheng L, Jiang J, Gao R, Wei S, Nan F, Li S, Kong B (2009) B7–H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer 19:1481–1486PubMedCrossRef
18.
Zurück zum Zitat Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, Lucia MS, Heinz DE, Papkoff J, Shroyer KR (2005) B7–h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 11:1842–1848PubMedCrossRef Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, Lucia MS, Heinz DE, Papkoff J, Shroyer KR (2005) B7–h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 11:1842–1848PubMedCrossRef
19.
Zurück zum Zitat Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR (2006) B7–H4 overexpression in ovarian tumors. Gynecol Oncol 100:44–52PubMedCrossRef Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR (2006) B7–H4 overexpression in ovarian tumors. Gynecol Oncol 100:44–52PubMedCrossRef
20.
Zurück zum Zitat Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A, Shroyer KR (2007) B7–H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 106:119–127PubMedCrossRef Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A, Shroyer KR (2007) B7–H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 106:119–127PubMedCrossRef
21.
Zurück zum Zitat Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED (2006) B7–H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Nati Acad Sci USA 103:10391–10396CrossRef Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED (2006) B7–H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Nati Acad Sci USA 103:10391–10396CrossRef
22.
Zurück zum Zitat Awadallah NS, Shroyer KR, Langer DA, Torkko KC, Chen YK, Bentz JS, Papkoff J, Liu W, Nash SR, Shah RJ (2008) Detection of B7–H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas 36:200–206PubMedCrossRef Awadallah NS, Shroyer KR, Langer DA, Torkko KC, Chen YK, Bentz JS, Papkoff J, Liu W, Nash SR, Shah RJ (2008) Detection of B7–H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas 36:200–206PubMedCrossRef
23.
Zurück zum Zitat Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL, Kim NW (2006) B7–H4 Is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 66:1570–1575PubMedCrossRef Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL, Kim NW (2006) B7–H4 Is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 66:1570–1575PubMedCrossRef
24.
Zurück zum Zitat Dube DH, Bertozzi CR (2005) Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 4:477–488PubMedCrossRef Dube DH, Bertozzi CR (2005) Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 4:477–488PubMedCrossRef
25.
Zurück zum Zitat Park GB, Song H, Kim YS, Sung M, Ryu JW, Lee HK, Cho DH, Kim D, Lee WJ, Hur DY (2009) Cell cycle arrest induced by engagement of B7–H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines. Immunology 128:360–368PubMedCrossRef Park GB, Song H, Kim YS, Sung M, Ryu JW, Lee HK, Cho DH, Kim D, Lee WJ, Hur DY (2009) Cell cycle arrest induced by engagement of B7–H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines. Immunology 128:360–368PubMedCrossRef
Metadaten
Titel
B7-H4 expression in various tumors determined using a novel developed monoclonal antibody
verfasst von
Yun Qian
Ling Shen
Linfang Cheng
Zhigang Wu
Hangping Yao
Publikationsdatum
01.09.2011
Verlag
Springer Milan
Erschienen in
Clinical and Experimental Medicine / Ausgabe 3/2011
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-010-0125-2

Weitere Artikel der Ausgabe 3/2011

Clinical and Experimental Medicine 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.